Prevalences of Gsα, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population
- 1 September 1998
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 49 (3) , 317-323
- https://doi.org/10.1046/j.1365-2265.1998.00515.x
Abstract
In thyroid tumours, ras, Gsα, p53 mutations and ret/PTC rearrangement have been reported with variable prevalences in different geographical regions. We studied the prevalence of these mutations and rearrangement in thyroid tumours in a Korean population. As MDM2 and Bcl-1 protein expressions have been suggested to be associated with p53 protein, we also studied possible relationships among them. Eleven cases of adenomatous goitre, eight cases of follicular adenoma, five cases of follicular carcinoma and 37 cases of papillary carcinoma were included in this study. To find mutations and rearrangement, RT–PCR, SSCP and/or direct sequencing, after subcloning if necessary, were used, and immunohistochemical stainings were performed for p53, MDM2 and Bcl-2 proteins in cases of papillary carcinoma. We could not find any rearrangement for ret/PTC-1, -2, -3 and mutation of Gsα. For the ras oncogene, K and H-ras mutations were not found, but N-ras mutations, point mutation of CAA to CGA in codon 61, were detected in one follicular adenoma (12.5%, 1/8) and one follicular carcinoma (33%, 1/3). p53 mutations were detected in only one case of papillary carcinoma (3%, 1/31: exon 8, codon 266 GGA → GAA). In 30 cases of papillary carcinoma without p53 mutation, the prevalences of positive immunohistochemical staining were 13.3% for p53 protein, 53.3% for MDM2 protein and 56.7% for Bcl-2 protein. While over-expression of p53 protein was not significantly related to that of MDM2 and Bcl-2 proteins, over-expression of MDM2 and Bcl-2 in papillary carcinoma were associated. ret/PTC rearrangement, Gsα, ras and p53 mutations are relatively rare in differentiated thyroid neoplasms from a Korean population, which may reflect genetic and environmental differences from patients in countries with high prevalences. P53 protein over-expression was noted in 13.3% of papillary carcinoma cases without p53 mutation and was not significantly related to MDM2 and Bcl-2 expression.Keywords
This publication has 23 references indexed in Scilit:
- Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformationJournal of Clinical Endocrinology & Metabolism, 1996
- Distribution of Gs-? activating mutations in human thyroid tumors measured by subcloningZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in JapanJournal of Clinical Endocrinology & Metabolism, 1995
- How loops, β sheets, and α helices help us to understand p53Cell, 1994
- p53: a Glimpse at the Puppet Behind the Shadow PlayScience, 1994
- Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid glandThe Journal of Pathology, 1994
- p53 mutations in all stages of thyroid carcinomasJournal of Clinical Endocrinology & Metabolism, 1993
- Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction—primer-introduced restriction analysisCancer, 1993
- Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasiaJournal of Clinical Endocrinology & Metabolism, 1992
- Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reactionGenomics, 1989